InMode Ltd. (NASDAQ:INMD) Shares Bought by D.A. Davidson & CO.

D.A. Davidson & CO. grew its holdings in shares of InMode Ltd. (NASDAQ:INMD) by 5.7% during the fourth quarter, Holdings Channel reports. The firm owned 43,651 shares of the healthcare company’s stock after acquiring an additional 2,373 shares during the quarter. D.A. Davidson & CO.’s holdings in InMode were worth $729,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently modified their holdings of the company. Nisa Investment Advisors LLC raised its holdings in shares of InMode by 314.7% during the third quarter. Nisa Investment Advisors LLC now owns 3,550 shares of the healthcare company’s stock worth $60,000 after purchasing an additional 2,694 shares during the period. Quarry LP raised its holdings in shares of InMode by 154.3% during the third quarter. Quarry LP now owns 3,781 shares of the healthcare company’s stock worth $64,000 after purchasing an additional 2,294 shares during the period. National Bank of Canada FI raised its holdings in shares of InMode by 6.2% during the third quarter. National Bank of Canada FI now owns 9,985 shares of the healthcare company’s stock worth $169,000 after purchasing an additional 579 shares during the period. GW Henssler & Associates Ltd. acquired a new stake in shares of InMode during the third quarter worth $177,000. Finally, DGS Capital Management LLC acquired a new stake in shares of InMode during the third quarter worth $182,000. 68.04% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

INMD has been the subject of several recent research reports. Needham & Company LLC restated a “hold” rating on shares of InMode in a research report on Tuesday, February 4th. Barclays upped their price target on shares of InMode from $26.00 to $29.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 5th. Three analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $22.25.

InMode Stock Performance

InMode stock opened at $19.12 on Tuesday. The company has a 50-day simple moving average of $17.42 and a 200-day simple moving average of $17.33. The firm has a market capitalization of $1.33 billion, a P/E ratio of 8.14 and a beta of 2.13. InMode Ltd. has a one year low of $14.87 and a one year high of $23.46.

InMode Profile

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.